INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Volume 11, Number 9 • September 1990

The Official Journal of The Society of Hospital Epidemiologists of America

https://doi.org/10.1017/S0899823X00083744 Published online by Cambridge University Press

From SmithKline Biologicals

20 mcg/mL

Engerix-B®

Hepatitis B Vaccine (Recombinant)

Choice of dosing regimens

Alternate 0,1,2 month dosing regimen for certain populations*

20 mcg recombinant dose

Helps to ensure immune response in adult patients of all ages

	Engerix-B®	Recombivax HB®†
Adult dose (mcg)	20	10
Standard dosing regimen (0, 1 and 6 months)	✓	✓
Alternate 0, 1, 2 month dosing regimen for certain populations*	✓	
Published efficacy data: Neonates born of infected mothers'	✓	✓
VACTRAC ™–computer software for vaccination tracking and compliance	✓	
Bar-coded, unit-dose vials	✓	
Lowest cost per dose[2]	✓	

*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas and neonates born of infected mothers. When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended.

Lowest Cost Per Dose[2]

Extensively tested and well tolerated[‡]

State-of-the-art recombinant technology

14 million doses distributed in over 87 countries[3]

Switch to Engerix-B®

Can be used to complete a course of vaccination initiated with another hepatitis B vaccine[3,4]



†Hepatitis B Vaccine (Recombinant), MSD.
‡Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

Engerix-B®

Hepatitis B Vaccine (Recombinant)

See complete prescribing information In SK&F literature or *PDR*. The following is a brief summary.

INDICATIONS AND USAGE: 'Engerix-B' is indicated for immunization against infection caused by all known subtypes of hepabtis B virus. Immunization is recommended i' persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus.

CONTRAINDICATIONS: Hypersensitivity to yeast or any other component of the vaccme is a contraindication for use of the vaccine.

WARNINGS: Do not give additional injections to patients experiencing hypersensitivity alter an 'Engerix-B' injection (See CONTRAINDICATIONS)

Hepatitis B has a long incubation period Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis B infection at the time of vaccine administration Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

PRECAUTIONS: General: As with any percutaneous vaccme, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccme, delay administration, if possible. in persons with any febrile illness or active infection

Pregnancy: Pregnancy Category C Animal reproduction studies have not been conducted with 'Engerix-B' It is also not known whether 'Engerix-B' can cause fetal harm when administered lo a pregnant woman or can affect reproduction capacity Give 'Engerix-B' lo a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether 'Engerix-B' is excreted in human milk Because many drugs are excreted in human milk, use caution when giving 'Engerix-B' to a nursing woman

Pediatric Uu: 'Engerix-B' has been shown to be well tolerated and highly immunogenic in infants and children of att ages. Newborns also respond welt, maternally transferred antibodies do not interfere with the active immune response to the vaccme

ADVERSE REACTIONS: 'Engerix-B' is generally well tolerated During clinical studies involving over 10,000 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration we reported As with any vaccine, however, d is possible that expanded commercial use of the vaccine could reveal rare adverse reactions not observed in clinical studies.

Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between 'Engerix-B' and plasma-derived vaccines. In 36 clinical studies a total of 13.495 doses of 'Engerix-B' were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers. and healthy neonates All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of 'Engerix-B' Using a symptom checklist,' the most frequently reported adverse reactions were injection site soreness (22%). and fatigue* (14%) Other reactions are listed below

Incidence 1% to 10% of Injections: Induration; erythema; swelling; fever (>37 5°C); headache', dizziness.*

*Parent or guardian completed torms for children and neonates Neonatal checklist did not include headache, fatigue or dizziness

Incidence <1% of Injections: Pain; pruritus; ecchymosis, sweating: malaise, chills; weakness; flushing; tingling; hypotension; influenza-like symptoms; upper respiratory tract illnesses; nausea; anorexia; abdominal pain/cramps, vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck, arthralgia; myalgia; back pain; rash, urticaria; petechiae; erythema; somnolence. insomnia; irritability; agitation

Additional adverse experiences have been reported with the commercial use of 'Engerix-B' outside the United States. Those listed below are to serve as alerting information to physicians: Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms. abnormal liver function tests; migraine, syncope; paresis; neuropathy including hypoesthesia, paresthesia, Guillain-Barré syndrome and Bell's patsy, transverse myelitis; thrombocytopenia; eczema; purpura; herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances

Potential Adverse Experiences In addition, certain other adverse experiences *not observed* with 'Engerix-B' have *been* reported with Heptavax-B®† and/or Recombivax HB®‡ Those listed below are to serve as alerting information to physicians Optic neuritis

HOW SUPPLIED: 20 mcg/mL in Single-Dose Vials in packages of 1. 10 and 25 vials.

NDC 0007-3860-01 (package of 1)
NOC 0007-3860-11 (package of 10)
NDC 0007-3860-16 (package of 25)

10 mcg/0 5 mL in Single-Dose Vials in packages of 1 vial.

NOC 0007 3859-01(package of 1)

† plasma-derived, Hepatitis B Vaccine, MSD
‡ yeast-derived, Hepatitis B Vaccine, MSD.

Manufactured by **SmithKline Biologicals**, Rixensart, Belgium
Distributed by **Smith Kline &French Laboratories**
Division of SmithKline Beckman Corp. Philadelphia, PA 19101

Date of issuance Aug. 1989

BRS-EB L6

Engerix-B is a registered trademark of *SmithKline Beecham*

References:
1. Poovorawan Y. Sanpavat S. Pongpunlert W. et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA* 1989; 261(22):3278–3281.
2. Based on Medi-Span® Hospital Formulary Pricing Guide. December 1989. 3. Data on file, SK&F. 4. Bush L, Moonsammy G. Boscia I: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989;10:689.

https://doi.org/10.1017/S0899823X00083744 Published online by Cambridge University Press

VOLUME 11, NUMBER 9 SEPTEMBER 1990

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated, 6900 Grove Road. Thorofare, New Jersey 08086. Telephone (609) 848-1000

Subscriptions: Requests should be addressed to the publisher (except Japan) In Japan, contact Woodbell Incorporated, 4-Z-11, Kitakasai, Edogawaku Tokyo 134. Japan Subscription rates in the US and possessions: Individual One year—$60 00; Two years—$95.00; Three years--$125 00 Institutional One year-$70 00; Two years—$110 00 Three years--$150 00, Canada $18 00 additional each year all other countries $30 00 additional each year Single copies of current issues may be obtained for $8 00. United States and possessions; $16 00 all other countries.

Reprints: All requests to reprint or use material published herein should be addressed to Lester J Robeson, SLACK Incorporated 6900 Grove Road, Thorofare NJ 08086 For reprint orders and prices, contact Fran Micaletti at (609) 848-1000 Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of $1 00 per copy plus $.15 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970 This consent does not extend to other kinds of copying, such as for general distribution, resale. advertising and promotional purposes, or for creating new collective works

Change of address: Notice should be sent to the publisher six weeks in advance of effective date Include old and new addresses with zip codes The publisher cannot accept responsibility for undelivered copies Second-class postage is pad at Thorofare, New Jersey 08086. and additional entry points **Postmaster:** Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086

As of Volume 1, Number 1, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in *Index Medicus, Current Contents—Clinical Practice, Hospital Literature* Index, *Cumulative Index to Nursing and Allied Health Literature,* and Nursing Abstracts.

EDITORIAL OFFICES
Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher
Richard N. Roash

Publisher
John C. Carter

Editorial Director
Jennifer Kilpatrick

Production Editor
Shirley P. Strunk, ELS

Assistant Editor
Eileen C. Anderer

Circulation Manager
Lester J. Robeson, CCCP

Production Director
Christine Malin

Production Coordinator
Joanne Patterson

Publishing Director/ Advertising
Wayne McCourt

Pharmaceutical Group Sales Director
Michael LoPresti

Advertising Sales Representative
Jennine Kane

Classified/Recruitment Sales Manager
Michele Burch

Protection is our line.



Artist interpretation of microorganisms.

Protection. The key to our superior glove line.

At Johnson &Johnson Medical, Inc., we have a reputation that spans more than 20 years — years dedicated to the research and development of quality gloves that provide maximum protection, optimum fit and excellent touch sensitivity.

We engineer quality into every aspect of our gloves beginning with 100 percent on-line visual inspection of all latex gloves, and quality standards that far exceed those recommended by the FDA.

Our protective lines include NEUTRALON" Brown Surgical Gloves, MICRO-TOUCH" Latex Surgical Gloves, MICRO-TOUCH" Latex Medical Gloves, DISPOS-A-GLOVE:" Examination Gloves and both the new MAXXUS* Orthopaedic Surgical Gloves, and the longer cuff MICRO-TOUCH'" XI' Latex Medical Gloves.

Protection and Johnson &Johnson Medical, Inc. — an unbeatable combination.

For more information, contact your Johnson & Johnson Medical, Inc., Medical Specialties Sales Representative or call l-800-433-5009.



Johnson & Johnson
MEDICAL INC.

*TRADEMARK © JJM,INC. 1990

https://doi.org/10.1017/S0899823X00083744 Published online by Cambridge University Press